

# Original Research Article

## PREVALENCE OF MULTIDRUG RESISTANCE AMONG STAPHYLOCOCCUS SPECIES ISOLATED FROM CLINICAL SAMPLES

---

### ABSTRACT

**Aims:** One major thing that adds to antimicrobial resistance among bacteria is their potential to produce enzymes and biofilms, which remain noteworthy elements in their pathogenicity. This study aimed to determine the prevalence of multidrug resistance *Staphylococcus* species isolated from different clinical samples.

**Study design:** The study employed an experimental study design.

**Place and Duration of Study:** *Staphylococcus* species of clinical samples origin were obtained from the microbiology laboratory of two teaching hospitals in Ogbomosho, Oyo State, between April and October, 2023.

**Methodology:** Twenty-six (26) pre-identified *Staphylococcus* spp. were obtained from the microbiology laboratories of two teaching hospitals in Ogbomosho, Nigeria. The isolates were subjected to microscopic, and biochemical tests to confirm their identities. The testing for antibacterial susceptibility was carried out using the Kirby-Bauer disk diffusion technique. A modified crystal violet biofilm assay was used to determine the ability of the isolates to produce biofilm. Molecular characterization was carried out to identify bacteria with very high resistance to the used antibiotics using 16S rRNA.

**Results:** All the *Staphylococcus* species in this study showed varied degrees of prevalence. All the clinical bacterial isolates also showed 100% resistance to Amoxicillin/Clavulanate, Cefuroxime, Cloxacillin Meropenem, and Doxycycline, while the slightest resistance was observed for Gentamicin with 29.17%. The multiple antibiotic resistance index (MARI) for all the isolates was between 0.3 to 1.0, which is higher than the safe limit of 0.2, with a high percent (95.8 %) of the bacteria being MAR.

**Conclusion:** The biofilm and enzyme production abilities of the clinical bacteria were major factors that led to expanded resistance, as observed in this study.

**Keywords:** *Staphylococcus*, Multidrug Resistance, Clinical Samples, AMR, biofilm

### 1. INTRODUCTION

Resistance to multiple antimicrobials is known as multidrug resistance (MDR), and various studies have shown that there are different resistance mechanisms in these bacteria, while their distribution and interaction are primarily complex and unknown. Resistance among bacteria can occur naturally through genetic mutation or if one species acquires resistance from another. However, extended use of antimicrobials encourages mutation selection, rendering antimicrobials ineffective (Amenu, 2014). Antimicrobial resistance is induced by the overuse of antimicrobials, thus leading to microorganisms evolving a defense against drugs or certain strains of microbes developing a natural resistance to antimicrobials, which

become prevailing than the ones that are easy to defeat with medication (Jiregna&Nesrie, 2017).

Bacteria have the ability to acquire and transmit resistance to antimicrobial agents. Following the massive use of antibiotics in human treatments, bacteria have evolved several resistance mechanisms, including expression of the efflux pumps, target site modification, and metabolic inactivation, which contribute to drug resistance in multidrug-resistant bacteria (Shaik *et al.*, 2014). The role of coagulase-negative Staphylococci in causing antibiotic resistance infections has been shown in recent reports. Presently, some relevant clinical species such as *Staphylococcus epidermidis*, *Staphylococcus heamolyticus*, *Staphylococcus saprophyticus* and *Staphylococcus lugdunensis* have been reported (Franca *et al.*, 2021).

*Staphylococcus aureus*, a coagulase-positive bacterium, is known to cause many infections, even life-threatening diseases like bacteremia, endocarditis and necrotizing pneumonia. This is because of its virulence, which enables it to escape the immune system and cause severe harm to the host (Mahmood *et al.*, 2021). Some *Staphylococcus* species live in normal microflora on human skin and mucous membranes, where they are associated with wound and urinary tract infections. Infectious diseases remain the leading mortality and morbidity cause around the world, especially in developing countries.

Biofilm production plays a vital role in the virulence of *Staphylococcus species* by allowing the cells to persist in the human body and evade the host immune defense system (Szczyka *et al.*, 2016). Some *Staphylococcus* species form biofilms on or around medical equipment, such as central venous catheters and prosthetic heart valves (Giampero *et al.*, 2022). Biofilm protects bacteria from the effect of antibiotics; low metabolic activity of bacteria in biofilm lowers the uptake of antibiotics, making them develop a high level of antibiotic resistance and increased pathogenicity. *Staphylococcus* species produce enzymes such as cellulases, pectinases, protease, collagenase, and keratinase, which, once on the surface, interact with host components like fibronectin and plasminogen to trigger signal transduction and thereby enable the pathogens to colonize, persist and invade the host tissue (Berne *et al.*, 2015).

They facilitate the penetration spread of the pathogen in the host and cause the collapse and disintegration of the cellular structure, thereby aiding the pathogen in the production of disease (Pirvanescu *et al.*, 2014). These enzymes convert fibrinogen into fibrin, which forms the threads of a blood clot and contributes to its pathogenicity (John *et al.*, 2018). Lipases are crucial in lipid metabolism, which includes digestion, transport, and the processing of dietary lipids. Lipase activity is required for the colonization and persistence of bacterial pathogens like *Staphylococcus epidermidis* on human skin, the lipases of *S. aureus* have been shown to interfere with the host cell immune response (Jaeger *et al.*, 1994). Collagenase breaks down the peptide bond in collagen and assists in destroying extracellular structures, thereby encouraging the spread of infection and pathogenesis (Gerald *et al.*, 2007). This study aimed to determine the prevalence of multidrug resistance *Staphylococcus* species isolated from different clinical samples.

## 2. MATERIAL AND METHODS

### 2.1 Isolates

*Staphylococcus* species of clinical samples origin were obtained from the microbiology laboratory of two teaching hospitals in Ogbomosho, Oyo State, between April and October, 2023. The clinical origins of the isolates were diverse, as reported by the laboratory. The bacteria were obtained as pure culture and were already identified by the hospital microbiology laboratories. These were collected on sterilized agar slants and then transported to the microbiology laboratory of the Department of Pure and Applied Biology, LAUTECH, Ogbomosho, for further study.

## 2.2 Identification of the Clinical Isolates

The obtained bacterial isolates were earlier identified by the source hospital microbiology laboratory, but they were subjected to microscopic and some biochemical characteristics according to standard conventional procedures (Bergey's Manual, 2000), to ascertain their identity. The previously identified bacteria from the hospital were subjected to microscopic, colonial and biochemical tests using standard conventional procedures (Bergey's Manual, 2000) to ascertain their identity.

## 2.3 Antibiotic Susceptibility Testing

The antimicrobial susceptibility test of the bacteria was determined using the Kirby-Bauer disk diffusion method on Muller Hinton Agar (MHA) plates (Patel *et al.*, 2017). Standardized inoculums were swabbed on the prepared MHA plates, and antibiotic disks were aseptically placed on the swabbed plates. Antibiotics used (CM-12-8PR100, product of Rapid Labs, UK) include Ceftazidime (30µg), Cefuroxime (30µg), Ceftriaxone (30µg), Gentamicin (10µg), Erythromycin (5µg), Cloxacillin (5µg), Ofloxacin (5µg), and Amoxicillin/Clavulanate (30µg). Bacterial isolates that showed 75% to the first eight (8) antibiotics used were further subjected to another four antibiotics namely; Meropenem (10µg), Doxycycline (30µg), Imipenem (10µg), Levofloxacin (5µg), products of BIO RAD (California, USA). The plates were incubated at 37°C overnight. Zones of inhibition were measured to determine susceptibility patterns, and results were compared with the Clinical and Laboratory Standard Institute (CLSI, 2018).

The multiple antibiotic resistance index (MARI) was calculated as:

$$\text{MAR Index} = \frac{a}{b} \text{-----} \quad (i)$$

Where a is the number of antibiotics an isolate is resistant to, and b is the total number of antibiotics used in the study

## 2.4 Biofilm Production Ability of the Bacterial Isolates

The bacterial isolates were assessed on their ability to produce biofilm, using a modified crystal violet assay according to a method described by Shukla *et al.* (2017). Bacteria were grown in nutrient broth (NB) overnight and diluted at a ratio 1:10 with fresh sterile NB in microtiter plates, then incubated for 48 hours at 37°C (Amao *et al.*, 2019). The microtiter plates were turned over, washed and then, 0.01 % of crystal violet solution was introduced. The plates were washed and vigorously blotted after 15 minutes incubation and then allowed to dry overnight. The quantification of the formed biofilms was performed at 492 nm on a HALO MPR-96 visible microplate reader after adding 125µL of 30% acetic acid solution, followed by incubation at room temperature for 15 mins. Results were interpreted as weak, moderate, and strong biofilm formers groups, according to Singh (2017).

## 2.5 Molecular Characterization of Isolates

Molecular characterization based on 16S rRNA was carried out on the isolates that showed greater than 75 % resistance to the second set of antibiotics used, with the primer pair 27F (AGAGTTTGATCMTGGCTCAG) and 1525R (AAGGAGGTGWTCCARCCGCA). Assembled nucleotide sequences were analyzed for similarities on the National Centre for Biotechnology Information site (NCBI) using the BLASTN tool. The information was used for phylogenetic analysis on MEGA X (USA), and the data were submitted to the NCBI data bank.

## 2.6 Determination of Enzyme Production Abilities of Bacterial Isolates

### 2.6.1 Pectinase Activity Assay

Assay for pectinase activity was carried out for the bacteria using the method of Kavuthodiet *al.* (2015). Clearance zone on agar plates were determined and recorded as positive results.

### 2.6.2 Protease Activity Assay

Casein agar medium was prepared as described by Larone (1993). The bacteria isolates were inoculated on casein agar plates and incubated overnight at 37° C. A clear zone indicates a positive test result.

### 2.6.3 Keratinase Activity Assay

The assay for keratinase was carried out according to the method described by Alwakeelet *al.* (2021). The inhibition zone was read and recorded as positive.

### 2.6.4 Cellulase Activity Assay

This assay was done to determine the ability of bacteria isolates to break down cellulose, employing the method of Miller (1959).

### 2.6.5 Collagenase Assay

Production medium for collagenase contained in 500 ml distilled water includes gelatin- 10 g; NaCl-0.05 g, H<sub>2</sub>PO<sub>4</sub>; 0.25 g, Mg SO<sub>4</sub>- 0.1 g, Peptone- 2.5 g, Agar- 8 g. The production medium was sterilized, and 20 ml of each was dispensed into the petri dish and allowed to solidify. Overnight pure culture of 0.5 ml was inoculated into the collagenase medium and incubated at 37 °C; the clearance zone was taken as a positive test. The wider the zone, the higher the potential to produce collagenase enzyme.

### 2.7 Statistical Analyses

Data analyses were based on the average of three replicates from independent studies. Statistical analyses of these averages were analyzed using One-way analysis of variance (ANOVA) in SPSS version 20 software at a 95 % significance level.

## 3. RESULTS AND DISCUSSION

The confirmatory test for collected bacterial isolates showed that 24 (92 %) of the 26 isolates were Gram positive as reported by the hospital laboratories, while 2 (8 %) showed different Gram reaction status (Table 1). Table 2 shows the results of antibacterial susceptibility testing of bacterial isolates to selected antibiotics. *Staphylococcus* species resisted Amoxicillin/Clavulanate, Cloxacillin, Cefuroxime (100 % resistance), and Ceftazidime (92 %). In this study, the vast majority of the bacterial isolates showed a multidrug resistance pattern, which is similar to the study conducted by Ehssan *et al.* (2022), who reported 89.2 % resistance and that of Kahsay *et al.* (2014) who also reported 82.3% resistance among *Staphylococcus* species. In contrast, Campanile *et al.* (2015) reported a resistance rate of 35.8%. The differences in resistance profile may be due to differences in infection epidemiology, prescription patterns, and the population's socio-demographic features (Kim *et al.*, 2015).

Table 1: Biochemical Tests of all obtained *Staphylococcus* Isolates

Isolate	Gram Reaction	Catalase Test	Oxidase Test	Coagulase Test	Haemolysis Test	Gas Prd Test	Nitrate Test	Glucose Prd Test
---------	---------------	---------------	--------------	----------------	-----------------	--------------	--------------	------------------

A1	+	+	-	-	-	+	+	+
A2	+	+	-	+	+	-	+	+
A3	+	+	-	-	+	+	+	+
A4	+	+	-	-	-	+	+	+
A5	+	+	-	-	-	+	+	+
B3	+	+	-	+	-	-	+	+
B5	+	+	-	-	+	+	+	+
B9	+	+	-	-	-	+	+	+
B12	+	+	-	+	+	+	+	+
B14	+	+	-	-	+	+	+	+
C2	+	+	-	-	+	+	-	+
C3	+	+	-	-	+	+	-	+
C4	+	+	-	-	+	+	-	+
C5	+	+	-	-	-	-	-	+
C8	+	+	-	-	-	+	+	+
C10	+	+	-	+	-	+	+	+
C11	+	+	-	-	+	+	+	+
C16	+	+	-	-	+	+	+	+
A14	+	+	-	-	+	+	+	+
A15	+	+	-	-	+	+	+	+
A16	+	+	-	-	+	+	+	+
B16	+	+	-	-	+	+	+	+
B17	+	+	-	-	+	+	-	+
A13	+	+	-	-	+	+	+	+
C6	-	+	-	-	-	-	+	+
C7	-	+	-	-	+	-	+	-

Key: Positive (+); Negative (-)

Table 2: Antibiotic Susceptibility Test *Staphylococcus* Isolates

Isolate	AUG	CAZ	CRX	GEN	CTR	OFL	ERY	CXC	% Resistance
B9	R	R	R	S	R	R	R	R	87.5
C10	R	R	R	R	R	S	R	R	87.5
C2	R	R	R	S	R	R	R	R	87.5
B16	R	R	R	R	R	R	R	R	100
B14	R	R	R	S	R	R	R	R	87.5
C11	R	R	R	S	R	S	R	R	75
A15	R	I	R	S	S	R	R	R	62.5
A5	R	R	R	S	R	S	I	R	62.5
B17	R	R	R	S	R	S	I	R	62.5
C4	R	R	R	S	S	S	R	R	62.5
B3	R	I	R	R	S	R	R	R	75
A1	R	R	R	S	R	I	I	R	62.5
C16	R	R	R	S	R	R	R	R	87.5

A2	R	R	R	S	R	S	R	R	75
A3	R	R	R	S	R	S	R	R	75
A14	R	R	R	S	R	S	I	R	62.5
B5	R	R	R	S	R	S	R	R	75
A4	R	R	R	S	R	S	S	R	62.5
C5	R	R	R	R	R	R	R	R	100
C8	R	R	R	R	R	R	R	R	100
B12	R	R	R	S	R	R	R	R	87.5
A16	R	R	R	R	R	R	R	R	100
A13	R	R	R	S	R	S	S	R	62.5
C3	R	R	R	R	R	S	R	R	87.5
%	of	100	91.67	100	29.17	87.5	45.83	75	100
Resistance									

KEYS: AUG: Amoxicillin/ Clavulanate (30µg), CAZ: Ceftazidime (30µg); CRX:Cefuroxime (30µg); GEN: Gentamicin (10µg); CTR : Ceftriazone (30µg); OFL: Ofloxacin (5µg); ERY:Erythromycin (5µg); CXC: Cloxicillin (5µg) R:Resistance; S: Sensitive; I:Intermediate

All the bacterial isolates were most sensitive to Gentamicin (70 %) and least sensitive to Ofloxacin (54 %). The antibiotic susceptibility profile results for the bacteria showed >75 % resistance, as represented in Table 3. Many studies have shown that Meropenem has greater efficacy than Imipenem (Piller *et al.*, 2008). However, other researchers have shown different findings with this antibiotics, a resistance of 62.5 % was reported from Nepal (Parajuli *et al.*, 2017), 79.3 % from Vietnam (Tran *et al.*, 2017), and 69.68 % from Mexico (Andres *et al.*, 2019). These bacterial isolates have a high resistance rate to the standard antibiotics used singly or combined.

Table 3: Antibiotic Susceptibility Test for *Staphylococcus* Isolates with Resistance >75 %

Isolate	MERO	DOXY	IMI	LEVO	% Resistance
B14	R	R	R	R	100
B16	R	R	I	R	75
B9	R	R	R	R	100
C16	R	R	R	R	100
B5	R	R	R	S	75
B3	R	R	R	R	100
A3	R	R	R	R	100
C1	R	R	R	S	75
C10	R	R	R	R	100
C5	R	R	R	R	100
C2	R	R	R	S	75
A16	R	R	R	S	75
B12	R	R	R	R	100
A2	R	R	R	R	100
C3	R	R	R	S	75
C8	R	R	R	S	75

Key: MERO: Meropenem (10µg); DOXY: Doxycycline (30µg); IMI: Imipenem (10µg); LEVO: Levofloxacin (5µg); R: Resistance; S: Sensitive; I:Intermediate

The findings on Imipenem and Meropenem are disturbing since they are the last line of drugs used in the treatment of infections caused by multidrug-resistant bacteria. Imipenem-resistant strains are always resistant to other antimicrobial drugs, and the outcome of their resistance appears worse in the area of mortality and morbidity (Ameen *et al.*, 2015). The total resistance of the *Staphylococcus* species was observed for Meropenem and Doxycycline, followed by imipenem (94 %) and Levofloxacin (63%). Table 4 summarizes the sensitivity of the bacterial isolates to different antibiotics. Fig 1 shows the resistance pattern of the *Staphylococcus* species to the different antibiotics used in this study; 100% resistance was observed for Amoxicillin/Clavulanate, Cloxacillin, Cefuroxime, Meropenem, and Doxycycline. Most bacteria were resistant to four or five different antibiotics, proving them to be multidrug-resistant (Table 5). The multiple antibiotic resistance index (MARI) for all bacteria ranges from 0.3 to 1.0, higher than the acceptable limit of 0.2 (Table 5). The antibiotic resistance index for all the bacterial isolates is high, ranging from 0.3 to 1.0 and higher than the recommended safe limit of 0.2. The reason for resistance to these carbapenems may result from carbapenemase enzymes, which are clinically important because of their ability to hydrolyze all or most of the beta-lactam drugs.

Table 4: Summary of the Sensitivity Pattern of *Staphylococcus* Isolates to different Antibiotics

Antibiotics	Sensitive	Intermediate	Resistance
Ceftazidime	0	2 (8 %)	22 (92 %)
Cefuroxime	0	0	24 (100 %)
Gentamicin	17 (71 %)	0	7 (29 %)
Ceftirazone	3 (12 %)	0	21 (88 %)
Erythromycin	2 (8 %)	4 (17 %)	18 (75 %)
Cloxacillin	0	0	24 (100 %)
Ofloxacin	12 (50 %)	1 (4 %)	11 (46 %)
Amoxicillin/ Clavulanate	0	0	24 (100 %)
Meropenem	0	0	16 (100 %)
Doxycycline	0	0	16 (100 %)
Imipenem	0	1 (6%)	15 (94 %)
Levofloxacin	6 (37 %)	0	10 (63 %)




Fig 1: Percentage of the Resistance Pattern of *Staphylococcus* Isolates to different Antibiotics

Table 5: Antibiotypes of selected antibiotics on *Staphylococcus* isolates and their multiple antibiotic resistance index

Isolate	Antibiotypes	MARI	Resistance Status
A1	Aug-Caz-Crx-Ctr-Ery-Cxc	0.5	MDR
A2	Aug-Caz-Crx-Ctr-Ery-Cxc-Mero-Doxy-Imi-levo	0.8	MDR
A3	Aug-Caz-Crx-Ctr-Ery-Cxc Mero-Doxy-Imi-levo	0.8	MDR
A4	Aug-Caz-Crx-Ctr-Ery-Cxc	0.5	MDR
A5	Aug-Caz-Crx-Ctr-Ery-Cxc	0.5	MDR
A14	Aug-Caz-Crx-Ctr-Cxc	0.4	MDR
A13	Aug-Caz-Crx-Ctr-Cxc	0.4	MDR
A15	Aug-Crx-Ctr-Ery-Cxc	0.4	MDR
A16	Aug-Caz-Crx-Gen-Ctr-Ofi-Ery-Cxc-Mero-Doxy-levo	0.9	MDR
B3	Aug-Caz-Crx-Ctr-Ery-Cxc- Mero-Doxy-Imi-levo	0.8	MDR
B5	Aug-Caz-Crx-Ctr-Ery-Cxc- Mero-Doxy-Imi-levo	0.8	MDR
B9	Aug-Cax-Crx-Ctr-Ofi-Ery-Cxc-Mero-Doxy-Levo	0.8	MDR
B12	Aug-Caz-Crx-Ctr-Ery-Cxc- Mero-Doxy-Imi-levo	0.8	MDR
B14	Aug-Caz-Crx-Ctr-Ery-Cxc- Mero-Doxy-Imi-levo	0.8	MDR
B16	Aug-Caz-Crx-Gen-Ctr-Ofi-Ery-Cxc-Mero-Doxy-levo	0.9	MDR
B17	Aug-Caz-Crx-Ery-Cxc	0.4	MDR
C2	Aug-Caz-Crx-Ctr-Ery-Cxc- Mero-Doxy-Imi-levo	0.8	MDR
C3	Aug-Caz-Crx-Ctr-Ery-Cxc- Mero-Doxy-Imi-levo	0.8	MDR
C4	Aug-Caz-Crx-Ctr-Ery-Cxc	0.5	MDR
C5	Aug-Caz-Crx-Gen-Ctr-Ofi-Ery-Cxc- Mero-Doxy-Imi-levo	1.0	MDR
C8	Aug-Caz-Crx-Ctr-Ery-Cxc	0.5	MDR
C10	Aug-Caz-Crx-Ctr-Ery-Cxc Mero-Doxy-Imi-Levo	0.8	MDR

C11	Aug-Caz-Crx-Ctr-Ery-Cxc- Mero-Doxy-Imi-Levo	0.8	MDR
C16	Aug-Caz-Crx-Ctr-Ery-Cxc-Mero-Doxy-Imi-Levo	0.8	MDR

KEYS: AUG: Amoxicillin/Clavulanate (30 µg); CAZ: Ceftazidime (30 µg); CRX: Cefuroxime (30 µg); GEN: Gentamicin (10µg); CTR: Ceftriazone (30µg); OFL: Ofloxacin (5 µg); ERY:Erythromycin (5 µg); CXC: Cloxicillin (5 µg); MERO: Meropenem (10 µg); DOXY: Doxycycline (30 µg); IMI: Imipenem (10 µg); LEVO: Levofloxacin (5 µg); AMP: Ampicillin (10 µg), NIT: Nitrofurantoin( 30 µg); CPR: Ciprofloxacin (5µg); MARI: Multi-Antibiotic Resistance Index, MDR: Multidrug resistant.

The isolates' ability to produce biofilm is presented in Table 6. Thirteen (13) isolates (54.2 %) were moderate biofilm producers, five isolates (20.8 %) were weak biofilm formers, and six isolates, representing 25 %, were non-biofilm former. The production of biofilms by (75 %) of these bacteria might have aided their multiple antibiotic tolerance mechanisms like impermeability, rapid growth and influence drug resistance (Xi-Hui *et al.*, 2017). Biofilm production supports gene transfer among microorganisms through their various connection channels, thereby increasing antibiotic resistance (Singh *et al.*, 2017). The mutation also facilitates adjacent microcolonies in a biofilm, taking up free DNA and making the biofilms more antibiotic-resistant (Blair *et al.*, 2015). Bacteria in biofilms produce potential virulence factors to prolong infections to a more chronic disease state (Leneet *al.*, 2020) by suppressing immune responses.

Table 6: Biofilm Production ability of Isolated Bacteria

Isolate	Mean	Biofilm Former Group
C11	0.064±0.01	Non biofilm producer
C16	0.061±0.11	Non biofilm producer
A15	0.061±0.03	Non biofilm producer
B3	0.061±0.01	Non biofilm producer
B5	0.060±0.01	Non biofilm producer
C4	0.070±0.01	Non biofilm producer
A3	0.081±0.04	Weak biofilm former
A4	0.094±0.02	Weak biofilm former
B12	0.097±0.03	Weak biofilm former
B14	0.078±0.04	Weak biofilm former
C3	0.081±0.02	Weak biofilm former
A1	0.119±0.03	Moderate biofilm former
A2	0.123±0.01	Moderate biofilm former
A5	0.103±0.04	Moderate biofilm former
A13	0.126±0.02	Moderate biofilm former
A14	0.120±0.01	Moderate biofilm former
A16	0.151±0.03	Moderate biofilm former
B9	0.117±0.01	Moderate biofilm former
B16	0.119±0.04	Moderate biofilm former
B17	0.103±0.04	Moderate biofilm former
C2	0.121±0.03	Moderate biofilm former
C5	0.119±0.02	Moderate biofilm former
C7	0.117±0.02	Moderate biofilm former
C10	0.119±0.02	Moderate biofilm former

Key: Value = mean ± Standard deviation.

The phylogenetic relatedness of the selected bacterial isolates, identifying the closest identity for each of the isolates, is presented in Fig. 2. *Staphylococcus* species in this study showed similarity with *Staphylococcus* species from the gene bank database. The accession

numbers of the isolates submitted to the Gene bank were presented in Table 7. The result shows that 77.8 % of these isolates could produce one or more enzymes, while 22.2 % of bacterial isolates proved otherwise (Table 8). Many of these bacteria isolates (77.8 %) have the potential to produce one or more enzymes, which make them metabolically active, possibly influencing their colonization of infection sites, pathogenicity and resistance to antimicrobial agents (Singh *et al.*, 2017).

Table 7: Selected *Staphylococcus* isolates with their Accession Number

Isolate Code	Isolate Identity	Accession Number
B14	<i>Staphylococcus haemolyticus</i>	OR367738
C16	<i>Staphylococcus xylosus</i>	OR367735
A3	<i>Staphylococcus epidermidis</i>	OR367734
C10	<i>Staphylococcus aureus</i>	OR367732
C5	<i>Staphylococcus warneri</i>	OR367730
B9	<i>Staphylococcus aureus</i>	OR367729
B12	<i>Staphylococcus haemolyticus</i>	OR367728
A2	<i>Staphylococcus aureus</i>	OR367727
B3	<i>Staphylococcus aureus</i>	OR367726
C2	<i>Staphylococcus aureus</i>	PQ643445

Table 8: Enzyme Assay for Selected Bacteria Isolates

Isolate Code	Accession Number	Pectinase	Protease	Keratinase	Cellulase	Collagenase
A2	OR367727	+	-	-	+	-
B9	OR367729	-	-	-	-	+
B12	OR367728	-	-	-	-	-
C10	OR367732	+	-	+	-	-
B3	OR367726	-	-	-	+	+
C16	OR367735	+	-	-	+	+
C5	OR367730	-	-	+	-	-
B14	OR367738	-	-	-	-	-
A3	OR367734	+	-	+	+	-
C2	PQ643445	-	-	-	-	-

KEY: + = Positive reaction; - = Negative reaction




Fig 2: Phylogenetic relationship of selected *Staphylococcus* isolates

#### 4. CONCLUSION

Resistance to the carbapenems class of antibiotics by multidrug-resistant clinical isolates is a growing concern in healthcare. *Staphylococcus* species are a major rising threat to public health and modern medicine due to their vast resistance to multiple antibiotics. Most of the bacteria collected from different clinical site samples in the two teaching Hospitals from Ogbomoso showed multiple resistance to all the antibiotics tested. The production of certain enzymes and biofilm formation by these microorganisms are essential factors that enhance their virulence, hence leading to multiple drug resistance. At times, errors from the Hospital laboratory scientists may occur in the area of bacteria identification, which affects antimicrobial stewardship and may contribute to multidrug resistance.

## REFERENCES

1. Amenu D. Antimicrobial resistance for enteric pathogens isolated from acute gastroenteritis patients. 2014.
2. Jiregna D, Nesrie S. Review on antibiotic resistance and its mechanism of development. *J Health Med Nurs*. 2017;1(3):1-17.
3. Shaik G, Sjatah N, Santosh KM. Medicinal plants as source of antibacterial agents to counter *Klebsiella pneumoniae*. *J Appl Pharm Sci*. 2014;4(01):135-147.
4. Franca A, Gaio V, Lopes N, Melo LDR. Virulence factors in coagulase negative *Staphylococci*. *Pathogens*. 2021;4:170.
5. Mahmood LJ, Anwer SS. Detection of vancomycin resistant gene in *Staphylococcus aureus* isolated from different clinical samples in Erbil city. *J Univ Bablon Pure Appl Sci*. 2021;1-10.
6. Szczuka E, Makowska N, Bosacka K, Słotwińska A, Kaznowski A. Molecular basis of resistance to macrolides, lincosamides and streptogramins in *Staphylococcus hominis* strains isolated from clinical specimens. *Folia Microbiol*. 2016;61:143–147.
7. Giampiero P, Davide C, Chiara M, Lucio M, Carla RA, Pietro S. Colonization and infection of indwelling medical devices by *Staphylococcus aureus* with an emphasis on orthopedic implants. *Int J Mol Sci*. 2022;23(11):5958.
8. Berne C, Ducret A, Hardy GG, Brun YV. Adhesins involved in attachment to abiotic surfaces by Gram-negative bacteria. *MicrobiolSpectr*. 2015;3:1-45.
9. Pirvanescu H, Marston G. Enzymatic mechanisms and bacterial virulence. *J Bacteriol Res*. 2014;6(4):217–223.
10. Weisel JW, Litvinov RI. Fibrin formation, structure, and properties. *SubcellBiochem*. 2017;82:405-456.
11. Jaeger KE, Ransac S, Dijkstra BW, Colson C, van Heuvel M, Misse O. Bacterial lipases. *FEMS Microbiol Rev*. 1994;15:29–63.
12. Clinical and Laboratory Standards Institute (CLSI). Performance standard for antimicrobial susceptibility testing: Twenty–second International Supplement. CLSI Document M100-522. 2018.
13. Tortora GJ, Funk BR, Case CL. *Microbiology: an introduction*. Pearson Benjamin Cummings; 2007.
14. Bergey DH, Holt JG. *Bergey's manual of determinative bacteriology*. 9th ed. 2000.
15. Patel C, Shah M, Singh S, Modi C, Shah P. Biofilm production and antimicrobial resistance in catheter-associated urinary tract infections (CAUTI) pathogens isolated from ICU patients. *Eur J Mol Clin Med*. 2021;8:3143-3152.

16. Shukla SK, Rao TS. Biofouling and biofilm processes section, water and steam chemistry division, Homi Bhabha National Institute. 2017;603 102.
17. Amao JA, Omojasola PF, Barooah M. Isolation and characterization of some exopolysaccharide-producing bacteria from cassava peel heaps. *Sci Afr*. 2019;4:e00093.
18. Kavuthodi B, Thomos S, Sebastian D. Coproduction of pectinase and biosurfactant by the newly isolated strain *Bacillus subtilis* BKDSI. *Br Microbiol Res J*. 2015;10(2):1-12.
19. Larone DH. Medically important fungi: a guide to identification. 2nd ed. Elsevier; 1993.
20. Alwakeel SS, Ameen F, AL Gwaiz H, Sonbol H, Algbamdi S, Moharram AM, Al-Bedak OA. Keratinase produced by *Aspergillus sydowii*, and *Fusarium brachygibbosum* isolated from human hair: yield and activity. *J Fungi (Basel)*. 2021.
21. Miller GL. Use of dinitrosalicylic acid reagent for determination of reducing sugar. *Anal Chem*. 1959;31(3):426-428.
22. Maglad EH, Altayb HN. Methicillin-resistant and multidrug-resistant *Staphylococcus* spp. in different clinical samples. *Open Access*. 2022;103432.
23. Kahsay AM, Abebe T. Isolation and antimicrobial susceptibility pattern of *Staphylococcus aureus* in patients with surgical site infection at Debre Markos Referral Hospital, Amhara Region, Ethiopia. *Arch Public Health*. 2014;72:16.
24. Campanile F, Bongiorno D, Perez M, Mongelli G, Sessa L, Benvenuto S, Gona F; AMCLI-S aureus Survey Participants; Varaldo PE, Stefani S. Epidemiology of *Staphylococcus aureus* in Italy: First nationwide survey, 2012. *J Glob Antimicrob Resist*. 2015.
25. Kim YJ, Oh DH, Song BR, Heo EJ, Lim JS, Moon JS, Park HJ, Wee SW, Sung K. Molecular characterization, antibiotic resistance, and virulence factors of methicillin-resistant *Staphylococcus aureus* strains isolated from imported and domestic meat in Korea. *Foodborne Pathog Dis*. 2015;12(5):390–398.
26. Piller CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. *Antimicrob Agents Chemother*. 2008;52(12):4388–4399.
27. Parajuli NP, Acharya SP, Mishra SK, Parajuli K, Rijal BP, Pokhrel BM. High burden of antimicrobial resistance among Gram-negative bacteria causing healthcare-associated infections in a critical care unit of Nepal. *Antimicrob Resist Infect Control*. 2017;6:1-9.
28. Tran GM, Ho-Le TP, Ha DT, Nguyen CH, Nguyen TS, Pham TTN, Nguyen TA, Nguyen DA, Hoang HQ, Tran NV, Nguyen TV. Patterns of antimicrobial resistance in intensive care unit patients: A study in Vietnam. *BMC Infect Dis*. 2017;17:429.
29. Uc-Cachón AH, Gracida-Osorno C, Luna-Chi IG, Jiménez-Guillermo JG, Molina-Salinas GM. High prevalence of antimicrobial resistance among Gram-negative isolated bacilli in intensive care units at a tertiary-care hospital in Yucatán, Mexico. *Medicina (Kaunas)*. 2019;55(9):588.

30. Ameen N, Memon Z, Shaheen S, Fatima G, Ahmed F. Imipenem resistance *Pseudomonas aeruginosa*: The fall of the final quarterback. *Pak J Med Sci*. 2015;31:561-565.
31. Xi-Hui L., Lee JH. Antibiofilm agents: a new perspective for antimicrobial strategy. *J Microbiol*. 2017;55(10):753–766.
32. Singh S, Singh SK, Chowdhury I, Singh R. Understanding the mechanism of bacteria biofilm resistance to antimicrobial agents. *Open Microbiol J*. 2017;11:53-62.
33. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol*. 2015;13:42–51.
34. Vestby LK, Gronset TG, Simm R, Nesse LL. Bacteria biofilm and its role in the pathogenesis of disease. *Antibiotics (Basel)*. 2020;9:59

UNDER PEER REVIEW